Athyrium Capital Management LP and Neuberger Berman Group LLC have closed Athyrium Opportunities Fund III at approximately $2.03 billion.

The fund will be used to make investments of $20 million to $300 million in commercial-stage healthcare companies in North America, Europe, Asia and Australia. The fund invests across the healthcare sector, including pharmaceuticals, medical products, diagnostics, healthcare services and healthcare information technology.

NB Alternatives Advisers LLC acts as a sub-adviser to the fund.